Role of Radical Cystectomy in Metastatic Bladder Cancer
- 1School of Medicine, Saint Louis University, St. Louis, MO 63104, USA
- 2Division of Urology, SSM Health Saint Louis University, St. Louis, MO 63110, USA
Abstract
Background/Objectives: The role of radical cystectomy (RC) in clinically metastatic (cM+) bladder cancer is unclear. This study aimed to identify national clinical practice patterns, factors associated with receipt of RC, and survival outcomes among patients with cM+ bladder cancer before the immunotherapy and antibody–drug conjugate era. Methods: In this retrospective cohort study, 18,360 patients with cM+ bladder cancer were identified from the National Cancer Database between 2006 and 2016. Demographics, comorbidities, cancer stage, and surgical outcomes were compared between patients who received RC and those managed without cystectomy (No RC). Multivariable logistic regression was used to identify factors associated with receiving RC, and overall survival was evaluated with Kaplan–Meier analysis and a multivariable Cox model with time measured from diagnosis, adjusted for age, sex, race, Charlson Comorbidity Index (CCI) score, clinical T stage, and histology. Results: Among the 18,360 patients with cM+ bladder cancer, 987 (5.4%) underwent RC. Patients who underwent RC were significantly younger, more likely to be White, and had lower CCI scores. Utilization of RC remained stable throughout the study period. On multivariable logistic regression, increasing age, Black race, and CCI score ≥ 3 were associated with lower odds of receiving RC, whereas cT3/4 disease and urothelial histology were predictors of receiving RC. Kaplan–Meier analysis demonstrated higher overall survival in the RC group. Postoperative mortality was 4.6% at 30 days and 23.6% at 90 days. Conclusions: Radical cystectomy was infrequently performed among patients with cM+ bladder cancer and was concentrated among younger, healthier patients. The survival difference between groups reflects selection and cannot be interpreted as a causal survival benefit from RC, since surgical intent, metastatic burden, and postoperative disease status are unavailable. Our findings provide a descriptive, population-level reference for comparison with future studies of RC in the current treatment era.
Related
- Optimal timing of adjuvant immunotherapy after radical cystectomy in muscle-invasive bladder cancer: from calendar-based to MRD-guided decision making
- FGFR3 Gene Alterations and Protein Expression in Paired TURBT and Radical Cystectomy Archival Specimens of Muscle-Invasive Bladder Cancer.
- Cytoreductive cystectomy combined with chemotherapy versus chemotherapy alone in the treatment of metastatic bladder cancer: A retrospective comparative study.
- Prognostic Impact of Nectin4 and IRF6 Expression in Patients Undergoing Radical Cystectomy for Muscle-Invasive Bladder Cancer.
- Predicting acute kidney injury after radical cystectomy for muscle-invasive bladder cancer.
BibTeX
@article{wong2026role,
title = {{Role of Radical Cystectomy in Metastatic Bladder Cancer}},
author = {Jonathan Wong and Ryan Wong and Zachary Hamilton and Luke Wang},
journal = {Journal of Clinical Medicine},
year = {2026},
month = nov,
doi = {10.3390/jcm15218586},
url = {https://www.mdpi.com/2077-0383/15/21/8586},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Role of Radical Cystectomy in Metastatic Bladder Cancer
AU - Jonathan Wong
AU - Ryan Wong
AU - Zachary Hamilton
AU - Luke Wang
PY - 2026
DA - 2026/11/04
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218586
UR - https://www.mdpi.com/2077-0383/15/21/8586
AB - Background/Objectives: The role of radical cystectomy (RC) in clinically metastatic (cM+) bladder cancer is unclear. This study aimed to identify national clinical practice patterns, factors associated with receipt of RC, and survival outcomes among patients with cM+ bladder cancer before the immunotherapy and antibody–drug conjugate era. Methods: In this retrospective cohort study, 18,360 patients with cM+ bladder cancer were identified from the National Cancer Database between 2006 and 2016. Demographics, comorbidities, cancer stage, and surgical outcomes were compared between patients who received RC and those managed without cystectomy (No RC). Multivariable logistic regression was used to identify factors associated with receiving RC, and overall survival was evaluated with Kaplan–Meier analysis and a multivariable Cox model with time measured from diagnosis, adjusted for age, sex, race, Charlson Comorbidity Index (CCI) score, clinical T stage, and histology. Results: Among the 18,360 patients with cM+ bladder cancer, 987 (5.4%) underwent RC. Patients who underwent RC were significantly younger, more likely to be White, and had lower CCI scores. Utilization of RC remained stable throughout the study period. On multivariable logistic regression, increasing age, Black race, and CCI score ≥ 3 were associated with lower odds of receiving RC, whereas cT3/4 disease and urothelial histology were predictors of receiving RC. Kaplan–Meier analysis demonstrated higher overall survival in the RC group. Postoperative mortality was 4.6% at 30 days and 23.6% at 90 days. Conclusions: Radical cystectomy was infrequently performed among patients with cM+ bladder cancer and was concentrated among younger, healthier patients. The survival difference between groups reflects selection and cannot be interpreted as a causal survival benefit from RC, since surgical intent, metastatic burden, and postoperative disease status are unavailable. Our findings provide a descriptive, population-level reference for comparison with future studies of RC in the current treatment era.
SN - 2077-0383
ER -